MAPT and supranuclear palsy, progressive, 1: PET studies employing tau ligands, such as (18F)Flortaucipir [132], have highlighted the association between tau pathology and cognitive performance across the AD continuum [133,134,135], PSP [136], CBS [137,138] and FTD [139] as well as tau co-pathology in Lewy body diseases [140].